NASDAQ · BEAM
Beam Therapeutics Inc.
$26.68-$2.16 (-7.49%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.27% below the high.
Loading market information…
OTC · NMTRQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
9 Meters Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
9 Meters Biopharma, Inc.’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow 9 Meters Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a clinical-stage biopharmaceutical firm, 9 Meters Biopharma, Inc. specialized in creating therapies for individuals in North America afflicted by rare digestive illnesses, various gastrointestinal disorders lacking effective treatments, and other debilitating conditions. Its primary therapeutic candidate was Vurolenatide, a long-acting injectable glucagon-like peptide-1, which had advanced to Phase 3 clinical trials for the management of short bowel syndrome. The company's pipeline also included NM-136, a humanized monoclonal antibody aimed at treating obesity and associated conditions; NM-102, a small molecule peptide designed to hinder antigen entry into the systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended to prevent acute graft versus host disease. Furthermore, it partnered on Larazotide, an 8-amino acid peptide undergoing Phase 2 clinical trials for multi-system inflammatory syndrome. Licensing arrangements were established with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, 9 Meters Biopharma, Inc. initiated a voluntary petition for liquidation under Chapter 7 of the U.S. Bankruptcy Code on July 17, 2023, in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$26.68-$2.16 (-7.49%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.27% below the high.
$1.20-$0.05 (-3.68%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.0% below the high.
$2.06-$0.12 (-5.3%)
Fate Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
CA$0.05CA$0.00 (0.0%)
MedMira Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
$0.03$0.00 (0.0%)
Acro Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 74.0% below the high.
CA$0.10-CA$0.03 (-23.08%)
Vaxil Bio Ltd.’s quoted price sits in the lower half of its reported 52-week range, 65.52% below the high.
$0.00-$0.00 (-24.08%)
CERo Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.08% below the high.
$0.00$0.00 (0.0%)
Item 9 Labs Corp.: Healthcare · Drug Manufacturers - Specialty & Generic.
